George Clinical scientific leaders and staff members enjoyed significant involvement in the 2021 American Society of Nephrology’s Kidney Week including contributions to abstracts, poster sessions, publications and presentations. Considering the organization’s deep history in kidney and metabolic clinical research, it is unsurprising yet inspiring to see such a broad set of renal research continuing despite […]
Read MoreWritten by Maria Ali in collaboration with Suzanna Phelps-Fredette Medical history began with a holistic approach Medical philosophy and practice dates back to the Indian Ayurvedic system of medicine and ancient Greek, Roman and Islamic physicians. Both took a holistic approach that considered the physical, mental and emotional health of a person as well as […]
Read MoreSYDNEY, October 14, 2021 – Graham Birrell, PhD, MBA, a researcher and neuropharmacologist with significant clinical research experience in the EU and Asia-Pacific region has joined George Clinical, a global scientifically-backed clinical research organization, as Head, Project Operations, APAC. Birrell will also join the scientific leadership of George Clinical with a neurology focus. In his […]
Read MoreThe International IgA Nephropathy Network held the 16th International Symposium on IgA Nephropathy September 21-23 and George Clinical scientific leader Professor Jonathan Barratt presented a key presentation during the first plenary session of the event. Barratt, the Mayer professor of renal medicine at the University of Leicester, presented “RNA Interference in IgAN” on the first day […]
Read MoreCiteline has named George Clinical as a finalist for their 2021 Clinical Research Team of the Year. Citeline, a comprehensive global R&D intelligence firm provides insights into the global clinical trial landscape and the development of clinical trial programs, selected the DARE-19 team of George Clinical based on their compelling international accomplishments during the height […]
Read MoreGlaxoSmithKline recently announced positive headline results from five studies of the Phase III ASCEND program conducted with George Clinical evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for patients with anemia due to chronic kidney disease (CKD). The ASCEND program showed that daprodustat met its primary […]
Read More
Excellent resources, proven experience and financial incentives make APAC a smart choice for First-in-Human and early phase clinical trials. Clinical trials are moving east Challenges to conducting trials in the West, especially recruitment difficulties, have made the APAC region a preferred destination for clinical trials. APAC offers a high availability of patients, worldwide accepted […]
Read MoreGeorge Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death and a sister company to George Clinical, has initiated two Phase III trials investigating its proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension. Recent hypertension guidelines recommend combination therapy as initial […]
Read MoreGeorge Clinical’s deep oncology research expertise was on display during the 2021 ASCO Annual Meeting. Several leaders were featured in sessions during the conference including Drs. Lee Schwartzberg, Ari VanderWalde, Herbert Loong, Ralph Boccia, Timothy Pluard and Jason Chandler. Schwartzberg is a co-author on 10 different abstracts that were highlighted in sessions during the virtual event […]
Read MoreSister organization George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, announced the appointment of Stefan König as Chief Executive Officer. George Medicines, a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading independent medical research institutes, […]
Read More
